Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT

November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana

Blood (2023) 142 (Supplement 1): 3717.

https://doi.org/10.1182/blood-2023-177989

Published: 2023

Journal Articles

Real-World Impact of Luspatercept on Patients with Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions and with Prior Exposure to Erythropoietin-Stimulating Agents: A United States Healthcare Claims Database Study

Kashyap Patel, Kirollos S. Hanna, Enrico Zanardo, Ali McBride, Victoria Barghout, Rui Song, Lynn Huynh, Derek Tang, Mihran Yenikomshian, Leslie A. Andritsos

Blood (2023) 142 (Supplement 1): 916.

https://doi.org/10.1182/blood-2023-173364

Published: 2023

Journal Articles

Real-World Retrospective Study of Non-Transfusion Dependent Patients with Myelodysplastic Syndromes Treated with Luspatercept: A Healthcare Claims Database Study

Leslie A. Andritsos, Kirollos S. Hanna, Enrico Zanardo, Ali McBride, Victoria Barghout, Rui Song, Lynn Huynh, Derek Tang, Mihran Yenikomshian, Kashyap Patel

Blood (2023) 142 (Supplement 1): 3808.

https://doi.org/10.1182/blood-2023-173375

Published: 2023

Journal Articles

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana

Blood (2023) 142 (Supplement 1): 2340.

https://doi.org/10.1182/blood-2023-178017

Published: 2023

Journal Articles

Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study

Mansoor N. Saleh, James B. Bussel, MD, Abderrahim Khelif, Paul Burgess, Ali El-Ali, Anuja Roy, Victoria Barghout, Mei Sheng Duh, Kelly M. Grotzinger, Abdulgabar Salama

Blood (2016) 128 (22): 3742.

https://doi.org/10.1182/blood.V128.22.3742.3742

Published: 2016

Journal Articles

Patient-Reported Health-Related Quality of Life Improves over Time in Patients with Chronic Immune Thrombocytopenia Receiving Long-Term Treatment with Eltrombopag

Abderrahim Khelif, Mansoor N. Saleh, Abdulgabar Salama, Paul Burgess, Maria do Socorro O Portella, Anuja Roy, Victoria Barghout, Jasmina I. Ivanova, Kelly M. Grotzinger, James B. Bussel, MD

Blood (2016) 128 (22): 3750.

https://doi.org/10.1182/blood.V128.22.3750.3750

Published: 2016

Journal Articles

Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia

Edmond L Toy, PhD, Francis Vekeman, MA, François Laliberté, MA, Bree Dority, PhD, Daniel Perlman, Victoria Barghout, MSPH, Mei Sheng Duh, MPH, ScD, Mark Lawrence Heaney, MD, PhD

Blood (2008) 112 (11): 665.

https://doi.org/10.1182/blood.V112.11.665.665

Published: 2008

Journal Articles

Compliance with Imatinib Mesylate Associated with Lower Health Resource Utilization and Costs for Patients with CML and GIST.

Rachel Halpern, PhD, Victoria Barghout, MSPH, Denise Williams, MD

Blood (2007) 110 (11): 5159.

https://doi.org/10.1182/blood.V110.11.5159.5159

Published: 2007

Journal Articles

Medical Costs of Adverse Events Associated with Patients Diagnosed with Chronic Myeloid Leukemia.

Erick Moyneur, MA, Victoria Barghout, MSPH, Williams Denise, MD, Salvado August, MD, Mallet David, MBA,MPP, Duh Mei Sheng, MPH,ScD

Blood (2006) 108 (11): 3323.

https://doi.org/10.1182/blood.V108.11.3323.3323

Published: 2006

NARROW

Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT

Real-World Impact of Luspatercept on Patients with Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions and with Prior Exposure to Erythropoietin-Stimulating Agents: A United States Healthcare Claims Database Study

Real-World Retrospective Study of Non-Transfusion Dependent Patients with Myelodysplastic Syndromes Treated with Luspatercept: A Healthcare Claims Database Study

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study

Patient-Reported Health-Related Quality of Life Improves over Time in Patients with Chronic Immune Thrombocytopenia Receiving Long-Term Treatment with Eltrombopag

Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia

Compliance with Imatinib Mesylate Associated with Lower Health Resource Utilization and Costs for Patients with CML and GIST.

Medical Costs of Adverse Events Associated with Patients Diagnosed with Chronic Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only